Delayed response in ipilimumab therapy

Journal of Community and Supportive Oncology

Volumn 12, Issue 3, 2014, Pages 109-110

  Megahed, Ahmed ^a   Faulhaber, Peter ^a   Phillips, Tycel ^b   Koon, Henry ^c  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CARBOPLATIN; INFLIXIMAB; IPILIMUMAB; METHYLPREDNISOLONE SODIUM SUCCINATE; PACLITAXEL; PREDNISONE;

ABDOMINAL MASS; ABDOMINAL PAIN; ADULT; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CASE REPORT; COLONOSCOPY; DIARRHEA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; IMMUNE RESPONSE; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; SHORT SURVEY; ULCERATIVE COLITIS;

EID: 84991593778     PISSN: 23307749     EISSN: None     Source Type: Journal    
DOI: 10.12788/jcso.0028     Document Type: Short Survey

References (4)

1. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648.
2. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
3. Margolin K. Ipilimumab in a phase II trial of melanoma patients with brain metastases. Oncoimmunology. 2012;1:1197-1199.
4. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412-7420.